These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26660439)

  • 21. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
    Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
    Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
    Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
    PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
    Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
    Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
    Vejpongsa P; Yeh ET
    Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
    Saleh EM
    Tumour Biol; 2015 Nov; 36(11):8985-92. PubMed ID: 26081617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
    Dickey JS; Osheroff N
    Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
    McClendon AK; Osheroff N
    Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
    Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
    Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pixantrone maleate for non-Hodgkin's lymphoma.
    Mukherji D; Pettengell R
    Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.
    Beeharry N; Di Rora AG; Smith MR; Yen TJ
    Cancer Biol Ther; 2015; 16(9):1397-406. PubMed ID: 26177126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
    Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
    Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delphinidin modulates the DNA-damaging properties of topoisomerase II poisons.
    Esselen M; Fritz J; Hutter M; Marko D
    Chem Res Toxicol; 2009 Mar; 22(3):554-64. PubMed ID: 19182879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress.
    Shinagawa H; Miki Y; Yoshida K
    Antioxid Redox Signal; 2008 May; 10(5):939-49. PubMed ID: 18162055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.